Search
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination … Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis].
Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsMipomersen
go.drugbank.com/drugs/DB05528ApprovedIt is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. … Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide.
Categories: DNA, Antisense, Compounds used in a research, industrial, or household settingAceclidine
go.drugbank.com/drugs/DB13262ApprovedAceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]
Sebelipase alfa
go.drugbank.com/drugs/DB11563ApprovedInvestigationalIt was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342] … [L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency.
Pegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigational[L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547] … Pegulicianine itself is a prodrug comprising three main fragments, one of which contains a fluorescence quencher that keeps the parent molecule optically inactive.
Categories: Compounds used in a research, industrial, or household settingClozapine
go.drugbank.com/drugs/DB00363ApprovedInvestigational[A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL. … Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent.
Categories: Dopamine D2 Receptor AntagonistsProducts: Aa-clozapine, CLOZAPIN 25 1A PHARMAVoxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalVoxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV) … Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].
Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsTeriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigational[A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic … Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent.[A251395] It is made up of the first amino(N)-terminal 34 amino acids of the human PTH.
Sipavibart
go.drugbank.com/drugs/DB21908ApprovedInvestigational[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025. … Sipavibart is a recombinant human IgG1 monoclonal antibody that is long-acting.
Nicorandil
go.drugbank.com/drugs/DB09220ApprovedInvestigationalWithdrawnNicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. … It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels.